- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03160976
Cryolipolysis on Localized Adiposity
May 22, 2017 updated by: Rodrigo Della Méa Plentz, Federal University of Health Science of Porto Alegre
Effects of Cryolipolysis on Localized Adiposity: Randomized Clinical Trial
The aim of this study is to analyze the effects of a single session of cryolipolysis on localized adiposity on women's abdomen.
This is a randomized controlled clinical trial that will include 28 women who will be randomly allocated into two groups: Control Group or Intervention Group.
The following assessments will be performed in both groups: ultrasonography and body composition at baseline and 30, 60 and 90 days after randomization and blood analysis at baseline and 15 and 30 days after randomization.
The expected main result at the end of this study is the reduction of the local subcutaneous fat tissue.
Study Overview
Detailed Description
Cryolipolysis is a non - invasive method for localized fat reduction wich uses low temperatures to induce an apoptotic and inflammatory response and consequent adipocyte death in the treated area.
Although the practice of this technique has been increasing, there are some gaps in the literature about the exact mechanism of action and only a few randomized clinical trials that proves its effectiveness and safety.
Then, the aim of this study is to analyse the effects of cryolipolysis on localized fat on women's abdomen.
This is a randomized controlled clinical trial that will include 28 women who will be randomized to Control Group (CG) or Intervention Group (IG).
The CG will perform the Evaluation Protocol with the following assessments: ultrasonography, thermographic analysis, blood analysis, bioimpedance and measurement of skinfold and abdominal circumference.
The IG will receive a single cryolipolysis's session on lower abdomen and the Evaluation Protocol.
The follow up for both groups is 90 days.
Expected main result at the end of the study is the reduction of the local subcutaneous fat tissue.
Study Type
Interventional
Enrollment (Anticipated)
28
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazil, 90050170
- Federal University of Health Science of Porto Alegre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female
- Age 18 to 45 or not being on menopause
- Sedentary according to International Physical Activity Questionnaire
- Body Mass Index lower than 27 Kg/m²
- Skinfold: more than 3 centimeters at the lower abdomen
Exclusion Criteria:
- Cryoglobulinemia
- Cold urticaria
- Paroxysmal cold hemoglobinuria
- Raynaud disease
- Pregnancy and Breastfeeding
- Cancer
- Vascular diseases
- Heart diseases
- Epidermal lesions at the site of application
- Autoimmune diseases
- Osteoporosis
- Metallic implants and pacemaker
- Alterations of sensibility
- Inflammatory process and active infection
- Abdominal hernia
- Abdominal muscle diastasis
- Diabetes
- Anemia
- Previous plastic surgery on the area
- Liver and kidney diseases
- Cognitive impairment that prevents conducting evaluations, as well as inability to understand and sign the informed consent form
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control Group
Subjects will only receive the Evaluation Protocol and will be followed for 90 days.
|
|
Active Comparator: Intervention Group
A single 50 minutes session of cold exposure with a cryolipolysis device.
The parameters will be: temperature -10°C and vacuum between 60 Kpas (at beginning) and 40 Kpas (until the end).
|
First, the demarcation of the lower abdomen area at the same landmarks of the ultrasonography will be done.
Secondly, the patient will be positioned on the stretcher in the supine position with a 45 ° elevation of the trunk.
In this position, to protect the region to be treated, a glycerine antifreeze membrane will be placed.
The treatment parameters will be: temperature of -10 ° C, treatment time of 50 minutes (first 3 minutes of heating at 42°C) and moderate vacuum pressure (60 - 40 Kpas).
The applicator will be chosen according to the size of the area of each subject and positioned in the target region.
At the end the skinfold will be released automatically, the antifreeze membrane removed and a manual massage will be carried out for five minutes to stimulate local blood reperfusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subcutaneous fat layer
Time Frame: Baseline, 30, 60 and 90 days after intervention.
|
Subcutaneous fat layer changes measured by ultrasonography and skinfold.
|
Baseline, 30, 60 and 90 days after intervention.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Abdominal circumference
Time Frame: Baseline, 30, 60 and 90 days after intervention.
|
Abdominal circumference changes measured by perimetry method.
|
Baseline, 30, 60 and 90 days after intervention.
|
Inflammatory profile
Time Frame: Baseline, 15 and 30 days after intervention.
|
Inflammatory profile analyzed through level of interleukin - 6, tumor necrosis factor - alfa, monocyte chemotactic protein-1 and leptin.
|
Baseline, 15 and 30 days after intervention.
|
Body fat mass
Time Frame: Baseline, 30, 60 and 90 days after intervention.
|
Body fat mass changes measured by bioimpedance.
|
Baseline, 30, 60 and 90 days after intervention.
|
Liver function
Time Frame: Baseline, 15 and 30 days after intervention.
|
Liver function analyzed through aspartate aminotransferase and alanine aminotransferase
|
Baseline, 15 and 30 days after intervention.
|
Kidney function
Time Frame: Baseline, 15 and 30 days after intervention.
|
Kidney function analyzed through creatinine and urea
|
Baseline, 15 and 30 days after intervention.
|
Lipids profile
Time Frame: Baseline, 15 and 30 days after intervention
|
Lipids profile analyzed through high density lipoprotein, low density lipoprotein, cholesterol, triglycerides and glucose levels.
|
Baseline, 15 and 30 days after intervention
|
Local temperature
Time Frame: 2 minutes before and 2 minutes after intervention and massage
|
Local temperature changes with cryolipolysis measured by thermographic analysis.
|
2 minutes before and 2 minutes after intervention and massage
|
Adverse effects
Time Frame: 15 days after intervention
|
Identification of possible adverse effects by patient report
|
15 days after intervention
|
Pain level
Time Frame: First minute, twenty-fifth minute, fiftieth minute after intervention and first minute during the massage
|
Pain level measured by analogue visual pain scale
|
First minute, twenty-fifth minute, fiftieth minute after intervention and first minute during the massage
|
Body weight and body mass index
Time Frame: Baseline, 30, 60 and 90 days after intervention.
|
Body weight and body mass index
|
Baseline, 30, 60 and 90 days after intervention.
|
Physical Activity
Time Frame: Baseline and every 15 days after intervention
|
Level of physical activity measured by the International Physical Activity Questionnaire
|
Baseline and every 15 days after intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Rodrigo DM Plentz, PhD, Federal University of Health Science of Porto Alegre
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 25, 2017
Primary Completion (Anticipated)
August 25, 2017
Study Completion (Anticipated)
October 25, 2017
Study Registration Dates
First Submitted
May 16, 2017
First Submitted That Met QC Criteria
May 17, 2017
First Posted (Actual)
May 19, 2017
Study Record Updates
Last Update Posted (Actual)
May 24, 2017
Last Update Submitted That Met QC Criteria
May 22, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ECLA2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Subcutaneous Fat
-
Northwestern UniversityCompleted
-
Cynosure, Inc.Completed
-
Riverchase DermatologyAllerganUnknownSubcutaneous FatUnited States
-
AllerganCompleted
-
Caliway Biopharmaceuticals Co., Ltd.Active, not recruitingSubcutaneous FatUnited States
-
Caliway Biopharmaceuticals Co., Ltd.Active, not recruitingSubcutaneous FatUnited States
-
Caliway Biopharmaceuticals Co., Ltd.CompletedSubcutaneous FatUnited States
-
Caliway Biopharmaceuticals Co., Ltd.Completed
-
Cynosure, Inc.Completed
-
Caliway Biopharmaceuticals Co., Ltd.Completed
Clinical Trials on Cryolipolysis
-
Universidade Cidade de Sao PauloUniversidade Federal de Sao CarlosCompleted
-
Cairo UniversityCompleted
-
Zeltiq AestheticsCompleted
-
Zeltiq AestheticsCompletedBody Fat DisorderUnited States
-
Sabrin Mohamed Taha AbdelwahabCompletedObese Women With PCOSEgypt
-
Zeltiq AestheticsCompleted
-
Zeltiq AestheticsCompletedBody Fat DisorderUnited States
-
Zeltiq AestheticsCompleted
-
Zeltiq AestheticsCompletedFat Reduction in the Upper ArmCanada